
|Videos|April 4, 2011
TAK-700 in Localized Prostate Cancer Clinical Trials
Author(s)Howard M. Sandler, MD
Dr. Howard Sandler from Cedars-Sinai Medical Center discusses the TAK-700 in Localized Prostate Cancer Clinical Trials
Advertisement
Howard M. Sandler, MD, MS, from Cedars-Sinai Medical Center, discusses the examination of hormonal and radiation therapy used in combination for localized prostate cancer. A new agent named TAK-700 is being examined in multiple studies for various types of prostate cancer.
Advertisement
Advertisement
Advertisement
Trending on OncLive
1
Vopimetostat Plus Daraxonrasib Yields 92% ORR in MTAP-Deleted, RAS-Mutant Pancreatic Cancer
2
Hematologists Highlight Top Data From ASCO 2026
3
Subcutaneous Isatuximab Administered Via OBI Approved in EU for Multiple Myeloma
4
INDEPENDENCE, Type II JAK Inhibitor Data Highlight Key MPN and AML Data Arriving at EHA 2026
5






































































